NCT03234179Not yet recruiting
A Prognosis and Predicting Genetic Study of Lung Cancer
Source: ClinicalTrials.gov · Last updated 1 Aug 2017 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Lung cancer is a leading cause of cancer mortality among adults worldwide. The incidence rates of lung cancer among never smoking females in some parts of East Asia are among the highest in the world. The adenocarcinoma of lung being the most frequently identified histological type is more weakly associated with smoking, and often occurs in females and never-smokers. Although family history of lung cancer has been associated with histological subtypes, the inherited susceptibility factors that affect specific histology are unknown. Genetic factors that determine individual predisposition to lung cancer have been identified via genome-wide association studies. These known common loci, however, explain only a small fraction of the familial risk of lung cancer. The hypothesis of this study is that there are genetic factors that confer inherited susceptibility among patients with primary non-small-cell lung cancer (NSCLC).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 26 Jul 2017
- Start date
- 1 Aug 2017
- Primary completion date
- 1 Aug 2020
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- Lung cancer
- NCT number
- NCT03234179
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Aug 2017 to the primary completion date, 1 Aug 2020
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients without the diagnosis of primary non-small cell lung cancer.
- Patients who are combined with other malignancy and ongoing chemotherapy / radiation therapy.
Other
- Patients combined with coagulopathy.
Who the study is looking for
- The patient's family (within third-degree relatives) has at least one diagnosed of primary non-small cell lung cancer.
- The patient was diagnosed of primary non-small cell lung cancer at the age \< 45 years old.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.